Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Immix Biopharma, Inc. < Previous 1 2 Next > U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Multiple Myeloma August 23, 2023 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma Announces Dr. Heather Landau, Memorial Sloan Kettering Cancer Center Amyloidosis Program Director, Joins Nexcella Scientific Advisory Board August 18, 2023 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma Announces Additional NXC-201 AL Amyloidosis Clinical Data Accepted for Oral Presentation at the 20th International Myeloma Society Annual Meeting (September 27-30, Athens Greece) August 16, 2023 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma Subsidiary Nexcella Announces NXC-201 Multiple Myeloma Clinical Data Abstract Accepted for Presentation at the 20th International Myeloma Society Annual Meeting July 25, 2023 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma Reports 2nd Positive Interim Clinical Trial Data Readout in Relapsed/Refractory Metastatic Colorectal Cancer in Ongoing Phase 1b/2a IMX-110 IMMINENT-01 Clinical Trial July 17, 2023 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma Subsidiary Nexcella Completes Initial NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site July 10, 2023 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma Subsidiary Nexcella Completes Pre-IND Meeting with FDA on NXC-201 US Clinical Trial June 26, 2023 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma Subsidiary Nexcella Appoints Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, to Board of Directors June 22, 2023 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma Subsidiary Nexcella Appoints Jeffrey H. Cooper, former Chief Financial Officer of BioMarin, to Board of Directors June 20, 2023 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma Subsidiary Nexcella Appoints Mary Sue Coleman, former Johnson & Johnson Independent Director, to Board of Directors June 16, 2023 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma Completes $5 Million At-The-Market Equity Offering Program June 14, 2023 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma Subsidiary Nexcella Appoints Henry McKinnell, Jr., former Chairman & CEO of Pfizer Inc., to Board of Directors June 12, 2023 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma Subsidiary Nexcella Announces Commencement of NXC-201 Engineering Batches at its U.S. CAR-T Manufacturing Site May 26, 2023 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 26th Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT) May 04, 2023 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma Announces Early Positive IMX-110 Interim Clinical Trial Data Demonstrating 100% Tumor Shrinkage in Advanced Metastatic Colorectal Cancer at the Lowest Dose of IMX-110 + BeiGene / Novartis Anti-PD-1 Antibody Tislelizumab May 03, 2023 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Nexcella, an Immix Biopharma subsidiary, Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in Light Chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris April 26, 2023 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Nexcella, an Immix Biopharma subsidiary, announces poster presentation at the European Society for Blood and Marrow Transplantation 49th Annual Meeting April 04, 2023 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Nexcella, an Immix Biopharma Subsidiary, Announces 2023 Haematologica Editorial Highlighting NXC-201 Efficacy In The Context of U.S. Food And Drug Administration Approved BCMA CAR T Cells March 31, 2023 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Nexcella, an Immix Biopharma Subsidiary, Announces New Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in AL Amyloidosis Patients + Additional Positive Multiple Myeloma Safety Data Demonstrating NXC-201 Outpatient CAR-T Treatment March 23, 2023 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma Confirms No Exposure to Silicon Valley Bank or Silvergate Bank March 10, 2023 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX ImmixBio to Discuss Recent Positive NXC-201 Clinical Data in AL Amyloidosis and Multiple Myeloma at the 35th Annual Roth Conference on March 14 March 06, 2023 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma Subsidiary Nexcella Enters into U.S. GMP Manufacturing Agreement to Expand Ongoing NXC-201 Phase 1b/2 Clinical Trial to the U.S. February 15, 2023 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma Announces Dosing of First 2 Patients in its IMX-110 + BeiGene/Novartis anti-PD-1 Tislelizumab Phase 1b/2a Combination Clinical Trial in Patients with Advanced Cancer February 07, 2023 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma Subsidiary Nexcella, Inc. Presents 42-Patient Interim Data, with 90% Overall Response Rate in Relapsed or Refractory Multiple Myeloma at NXC-201 Therapeutic Dose from its Phase 1 Expansion Trial at the 5th European CAR T-cell Meeting February 09, 2023 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma Doses Additional Patients in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial January 13, 2023 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma Subsidiary Nexcella, Inc. Announces Additional Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in Relapsed/Refractory AL Amyloidosis Patients, Duration of Response Not Yet Reached January 06, 2023 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Nexcella, Inc., a subsidiary of Immix Biopharma, announces poster presentation at the European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-cell Meeting December 28, 2022 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma Announces 16th Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial December 20, 2022 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX ImmixBio Ships Tislelizumab for Patient Dosing in its Combination Clinical Trial with IMX-110 in Advanced Solid Tumors December 19, 2022 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX Immix Biopharma in-licenses NXC-201, BCMA-targeted Next-Generation CAR-T Therapy Demonstrating High Complete Response Rate in Heavily Pre-Treated Multiple Myeloma (71% Complete Responses) and AL Amyloidosis (100% Complete Responses) December 14, 2022 From Immix Biopharma, Inc. Via GlobeNewswire Tickers IMMX < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
